Condensed Balance Sheet [Table Text Block]

	For the years ended December 31,
(In thousands)	2023			2022
Accounts receivable, net
Accounts receivable	$	125,379		$	131,474
Less: allowance for doubtful accounts		(2,000	)		(4,162	)
	$	123,379		$	127,312
Inventories, net
Finished products	$	35,582		$	37,139
Consumable supplies		25,864			31,275
Work in-process		1,731			2,449
Raw materials		8,981			6,771
Less: inventory reserve		(6,461	)		(3,574	)
	$	65,697		$	74,060
Other current assets and prepaid expenses
Prepaid supplies	$	6,177		$	7,918
Prepaid insurance		3,848			4,496
Taxes recoverable		4,211			8,191
Other receivables		2,610			13,105
Other		7,673			6,252
	$	24,519		$	39,962
Property, plant and equipment, net:
Machinery, medical and other equipment	$	138,776		$	136,048
Leasehold improvements		28,058			25,516
Furniture and fixtures		12,046			11,271
Building		18,885			18,314
Software		14,410			14,218
Automobiles and aircraft		12,701			12,808
Land		2,425			2,317
Construction in process		5,255			4,793
Less: accumulated depreciation		(157,127	)		(142,406	)
	$	75,429		$	82,879
Intangible assets, net:
Technologies	$	831,509		$	826,282
Customer relationships		315,799			314,854
Trade names		49,758			49,752
Covenants not to compete		12,916			12,911
Licenses		6,205			5,988
Product registrations		6,790			6,831
Other		6,000			5,861
Less: accumulated amortization		(488,694	)		(398,959	)
	$	740,283		$	823,520

	For the years ended December 31,
(In thousands)	2023		2022
Accrued expenses:
Employee benefits	$	28,952	$	33,765
Gross to net provision		9,420		6,477
Inventory received but not invoiced		1,653		7,830
Taxes payable		1,384		5,351
Commitments and contingencies		8,088		4,295
Clinical trials		7,624		4,700
Finance leases short-term		2,827		2,809
Royalties		1,544		2,323
Professional fees		3,470		1,820
Commissions		1,822		1,471
Contingent consideration		—		62
Contract liabilities		—		—
Other		23,302		27,366
	$	90,086	$	98,269
Other long-term liabilities:
Mortgages and other debts payable	$	7,709	$	9,098
Finance leases long-term		7,274		7,089
Contingent consideration		—		974
Contract liabilities		7		138
Other		12,199		10,072
	$	27,189	$	27,371

Notes Tables

Condensed Income Statement [Table Text Block]

	For the years ended December 31,
	2023			2022			2021
Revenues:
Revenue from products	$	—		$	—		$	—
Revenue from transfer of intellectual property and other		—			—			—
Total revenues		—			—			—
Costs and expenses:
Costs of revenue		739			2,347			1,279
Selling, general and administrative		46,359			46,882			66,483
Research and development		4,106			4,196			2,029
Gain on sale of GeneDx		—			(18,559	)		—
Total costs and expenses		51,204			34,866			69,791
Operating loss		(51,204	)		(34,866	)		(69,791	)
Other income and (expense), net:
Interest income		2,499			1,762			334
Interest expense		(12,460	)		(13,688	)		(21,297	)
Fair value changes of derivative instruments, net		(26	)		12			(58	)
Other income (expense), net		(16,593	)		(154,807	)		(9,013	)
Other expense, net		(26,580	)		(166,721	)		(30,034	)
Loss before income taxes and investment losses		(77,784	)		(201,587	)		(99,825	)
Income tax provision		(19	)		(10	)		(2	)
Net loss before investments and loss from subsidiaries		(77,803	)		(201,597	)		(99,827	)
Loss from investments in investees		(107	)		(383	)		(629	)
Net income (loss) from subsidiaries, net of taxes		(110,953	)		(126,425	)		70,313
Net loss	$	(188,863	)	$	(328,405	)	$	(30,143	)

Condensed Cash Flow Statement [Table Text Block]

	For the years ended December 31,
	2023			2022			2021
Cash flows from operating activities:
Net loss	$	(188,863	)	$	(328,405	)	$	(30,143	)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash interest		2,750			2,750			9,389
Amortization of deferred financing costs		1,154			1,093			722
Losses from investments in investees		107			383			629
(Income) loss from subsidiaries		110,953			126,425			(70,313	)
Equity-based compensation – employees and non-employees		11,414			18,509			13,632
Non-cash revenue from the transfer of intellectual property		—			—			(3,801	)
Realized gain on equity securities and disposal of fixed assets		(364	)		—			(2,981	)
Change in fair value of derivative instruments and equity securities		16,891			154,473			4,871
Loss on conversion of the 2025 Notes		—			—			11,111
Gain on sale of GeneDx		—			(18,559	)		—
Changes in other assets and liabilities		11,559			(14,993	)		10,970
Net cash used in operating activities		(34,399	)		(58,324	)		(55,914	)
Cash flows from investing activities:
Investments in investees		(5,000	)		—			(2,000	)
Subsidiary financing		(30,242	)		23,866			69,608
Proceeds from sale of investments		364			—			—
Proceeds from sale of equity securities		—			115,423			8,078
Net cash (used in) provided by investing activities		(34,878	)		139,289			75,686
Cash flows from financing activities:
Proceeds from the exercise of Common Stock options and warrants		(272	)		(774	)		1,080
Redemption of 2033 Senior Notes		(3,000	)		—			—
Net cash (used in) provided by financing activities		(3,272	)		(774	)		1,080
Net increase (decrease) in cash and cash equivalents		(72,549	)		80,191			20,852
Cash and cash equivalents at beginning of period		104,783			24,592			3,740
Cash and cash equivalents at end of period	$	32,234		$	104,783		$	24,592
SUPPLEMENTAL INFORMATION:
Interest paid	$	8,135		$	7,420		$	8,515
Income taxes paid, net of refunds	$	3,712		$	8,037		$	5,969
Non-cash financing:
Shares issued upon the conversion of:
Common Stock options and warrants, surrendered in net exercise	$	301		$	1,268		$	—
Issuance of common stock for acquisition of ModeX	$	—		$	221,662		$	—
Fair value of shares included in consideration from GeneDx Holdings	$	6,689		$	172,000		$	—